Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03448692 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate PF-06730512 in Adults With Focal Segmental Glomerulosclerosis (FSGS)
A Phase 2 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 2
- Development phase
- 47
- Enrollment target
NCT03448692 is a Phase 2 study that was terminated before completion, run by Pfizer. The registered enrollment target is 47 participants.
The verdict
NCT03448692, a Phase 2 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 47 participants
- Enrollment target
Study Summary
The purpose of this Phase 2 adaptive study is to evaluate the efficacy, safety, tolerability and pharmacokinetics of PF-06730512 following multiple intravenous infusions in adult subjects with FSGS.
Interventions
- DRUG PF-06730512
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2018-10-15 |
| Est. Completion | 2023-02-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03448692
The ClinicalTrials.gov registry entry for NCT03448692 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PF-06730512 is the first listed.
NCT03448692 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03448692 about?
NCT03448692 is a clinical study titled "A Study to Evaluate PF-06730512 in Adults With Focal Segmental Glomerulosclerosis (FSGS)". The purpose of this Phase 2 adaptive study is to evaluate the efficacy, safety, tolerability and pharmacokinetics of PF-06730512 following multiple intravenous infusions in adult subjects with FSGS.
What is the current status of trial NCT03448692?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 47 participants. The study started on 2018-10-15. Estimated completion is 2023-02-14.
What interventions are being tested in trial NCT03448692?
The interventions under investigation include: PF-06730512 (DRUG).
Who is sponsoring clinical trial NCT03448692?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.